A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers wi…

Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, Adult+8 more

~Estimated

~$10 – $8,750

Tyra Biosciences, IncNCT06915753

Phase 2

A Phase 2a, Multicenter, Randomized, Open-Label Study to Assess the Efficacy, Safety, and Tolerability of RBS2418 in Combination With Tremelimumab Plus Durvalumab for Participants With Advanced Unresectable Hepatocellular Carcinoma

RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity …

Advanced Unresectable Hepatocellular Carcinoma

~Estimated

~$10 – $8,750

Riboscience, LLC.NCT07175441